Securing the driving force for future growth through active R&D
Securing a globally recognized back-up pipeline

CU02 | Nonalcoholic steatohepatitis(NASH) treatment
Obesity treatment through remodeling of adipocytes
A new concept for NASH treatment using TPH1 inhibitors that do not penetrate the blood brain barrier (BBB).First, to investigate the principle of activating brown adipocyte tissue and induce beige adipocyte tissue through selective inhibition of peripheral TPH1, a synthetase of serotonin._Published in Nature Communication in 2015
Expanded indication to IBD treatment (inflammatory bowel disease) – Ulcerative colitis, Crohn’s disease
Capable of being designated an orphan drug (Carcinoid cancer, PAH)
CU04 | Cancer (c-Myc inhibitor)
Low-molecular-weight c-myc inhibitor
Developed a first-in-class bromodomain drug with a new mechanism of action for inhibiting selective and indirect c-myc transcription
Low-molecular compound who are resistant to existing targeted anticancer agents
Prolongs survival rates of patient with cancer (PD-L1 > 1% expression level) by using the combination with immune-oncology drug (lung cancer)
Less toxic to normal cells compared to existing colorectal cancer
Can expand Indications to various cancer types (prostate, colorectal, lung cancer)
CU05 | Cancer (Amigo2-PDK1 inhibitor)
Low-molecular-weight, orally administered cancer treatment
Developed a first-in-class AKT pathway with a new mechanism of action for inhibiting the combination of the AMIGO2-PDK1 PH domain
Expected to show efficacy against advanced lung cancer
Prolongs patient survival by significantly increasing expression level in tissues of cancer patients in proximal inflammation stage when the survival rate decreases
Less toxic to normal cells compared to existing lung cancer treatment
Indication can be expanded to treatment of breast, pancreatic cancer